Trodelvy patient reviews

For adult patients. Find the most frequently asked questions about TRODELVY Take a minute to review some of the most common questions about treatment with

The early-phase IMMU-132 study showed that the drug Trodelvy improved outcomes for patients living with metastatic triple-negative breast cancer. Trodelvy is a smart drug Smart drugs combine two molecules. Trodelvy is a combination of a chemotherapy drug and an antibody that delivers it specifically to cancer cells.

by LM Spring 2024 Cited by 61(TRODELVY) for This review summarizes the clinical development and the practical management of patients receiving sacituzumab govitecan.

Table 1. Sacituzumab govitecan (Trodelvy ) approval status to treat secondary breast cancer by subtype. What clinical evidence is there for Trodelvy in treating breast cancer? ASCENT (TNBC) The ASCENT trial compared Trodelvy with single-agent chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine) in 529 patients with secondary TNBC.

Trodelvy is Under Regulatory Review in the EU and in the United Neutropenic colitis occurred in 0.5% of patients. Withhold TRODELVY for Grade 3-4 diarrhea and resume when resolved to

occurred in 61% of patients treated with TRODELVY. Grade 3-4 neutropenia occurred in 47% of patients. Febrile neutropenia occurred in 7%. Withhold TRODELVY for absolute neutrophil count below 1500/mm3 on Day 1 of any cycle or neutrophil count below 1000/mm3 on Day 8 of any cycle. Withhold TRODELVY for neutropenic fever.

How successful is Trodelvy? Trodelvy has shown significant success in clinical trials. Patients treated with Trodelvy were three times more

Trodelvy has been approved in more than 35 countries and is undergoing multiple additional regulatory reviews worldwide for the treatment of adult patients with

For patients treated with TRODELVY, the median duration of treatment was 4.4 months (range: 0 to 23 months). Serious adverse reactions occurred in 27% of patients receiving TRODELVY. Serious adverse reactions in 1% of patients receiving TRODELVY included neutropenia (7%), diarrhea (4%), and pneumonia (3%).